Marie Wood

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. ncbi Second malignant neoplasms: assessment and strategies for risk reduction
    Marie E Wood
    Division of Hematology Oncology, University of Vermont, Burlington, VT 05405, USA
    J Clin Oncol 30:3734-45. 2012
  2. ncbi Primary care physicians' use of family history for cancer risk assessment
    Brian S Flynn
    Department of Medicine, College of Medicine, University of Vermont, Burlington, Vermont 05405, USA
    BMC Fam Pract 11:45. 2010
  3. ncbi Discrepancy between preference and actual adjuvant therapy for breast cancer
    Marie E Wood
    Department of Medicine, University of Vermont, Burlington, VT 05405
    Clin Breast Cancer 10:398-403. 2010
  4. ncbi Interviews with primary care physicians regarding taking and interpreting the cancer family history
    Marie E Wood
    Hematology Oncology Division, University of Vermont, Burlington, VT 05405, USA
    Fam Pract 25:334-40. 2008
  5. ncbi Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection
    Marie E Wood
    Department of Medicine, University of Vermont College of Medicine, Burlington 05405, USA
    Acta Cytol 53:410-5. 2009
  6. ncbi Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
    Steven M Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, 89 Beaumont Avenue Given Bldg E214, Burlington, VT 05405, USA
    Support Care Cancer 17:589-94. 2009
  7. ncbi Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing
    Wendy McKinnon
    Department of Pediatrics, University of Vermont College of Medicine, Burlington, VT 05401, USA
    J Genet Couns 16:433-56. 2007
  8. ncbi Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals
    Wendy McKinnon
    Familial Cancer Program of the Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05401, USA
    Fam Cancer 8:363-9. 2009
  9. ncbi Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer
    Susan Burdette-Radoux
    Vermont Cancer Center, University of Vermont, Burlington, Vermont 05401, USA
    Breast J 13:274-80. 2007
  10. ncbi Selecting adjuvant endocrine therapy for breast cancer
    Jonathan D Eneman
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Oncology (Williston Park) 18:1733-44, discussion 1744-5, 1748, 1751-4. 2004

Research Grants

  1. Factors Influencing Use of Cancer Genetics by Physicians
    Marie Wood; Fiscal Year: 2002
  2. Factors Influencing Use of Cancer Genetics by Physicians
    Marie Wood; Fiscal Year: 2004

Collaborators

Detail Information

Publications10

  1. ncbi Second malignant neoplasms: assessment and strategies for risk reduction
    Marie E Wood
    Division of Hematology Oncology, University of Vermont, Burlington, VT 05405, USA
    J Clin Oncol 30:3734-45. 2012
    ....
  2. ncbi Primary care physicians' use of family history for cancer risk assessment
    Brian S Flynn
    Department of Medicine, College of Medicine, University of Vermont, Burlington, Vermont 05405, USA
    BMC Fam Pract 11:45. 2010
    ..Family history (FH) assessment is useful in identifying and managing patients at increased risk for cancer. This study assessed reported FH quality and associations with physician perceptions...
  3. ncbi Discrepancy between preference and actual adjuvant therapy for breast cancer
    Marie E Wood
    Department of Medicine, University of Vermont, Burlington, VT 05405
    Clin Breast Cancer 10:398-403. 2010
    ..Pretreatment preferences for adjuvant therapy were examined and compared with actual treatment received...
  4. ncbi Interviews with primary care physicians regarding taking and interpreting the cancer family history
    Marie E Wood
    Hematology Oncology Division, University of Vermont, Burlington, VT 05405, USA
    Fam Pract 25:334-40. 2008
    ..The cancer family history can be used to stratify risk and guide management regarding screening and prevention of cancer...
  5. ncbi Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection
    Marie E Wood
    Department of Medicine, University of Vermont College of Medicine, Burlington 05405, USA
    Acta Cytol 53:410-5. 2009
    ..To evaluate ductal lavage (DL) performance in women with known breast cancer and to assess cell yield from contralateral high-risk breasts...
  6. ncbi Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
    Steven M Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, 89 Beaumont Avenue Given Bldg E214, Burlington, VT 05405, USA
    Support Care Cancer 17:589-94. 2009
    ..The present study evaluated a more convenient single-day three-drug antiemetic regimen for patients receiving moderately emetogenic chemotherapy...
  7. ncbi Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing
    Wendy McKinnon
    Department of Pediatrics, University of Vermont College of Medicine, Burlington, VT 05401, USA
    J Genet Couns 16:433-56. 2007
    ..We conclude that this type of forum provides a valuable opportunity for BRCA carriers and their families to receive updated medical information, share personal experiences, provide and receive support, as well as change health behaviors...
  8. ncbi Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals
    Wendy McKinnon
    Familial Cancer Program of the Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05401, USA
    Fam Cancer 8:363-9. 2009
    ..There were no reports of job discrimination. Results suggest fear of GD is prevalent, yet data do not support evidence that GD exists...
  9. ncbi Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer
    Susan Burdette-Radoux
    Vermont Cancer Center, University of Vermont, Burlington, Vermont 05401, USA
    Breast J 13:274-80. 2007
    ....
  10. ncbi Selecting adjuvant endocrine therapy for breast cancer
    Jonathan D Eneman
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Oncology (Williston Park) 18:1733-44, discussion 1744-5, 1748, 1751-4. 2004
    ..Finally, four cases illustrating these difficult decisions will be discussed, with recommendations for treatment...

Research Grants3

  1. Factors Influencing Use of Cancer Genetics by Physicians
    Marie Wood; Fiscal Year: 2002
    ..abstract_text> ..
  2. Factors Influencing Use of Cancer Genetics by Physicians
    Marie Wood; Fiscal Year: 2004
    ....